Chronic Pain Clinical Trial
Official title:
The Breathe-(H)IT Trial: Multimodal High Intensity Training to Improve Diaphragm Functioning in Persons With Chronic Nonspecific Low Back Pain
This randomized controlled trial aims to investigate 1) the effects of high intensity training (HIT) compared to moderate intensity training (MIT) on diaphragm muscle strength, -endurance, -fatigue and -activation, 2) to which extent these changes in diaphragm functioning are related to changes in cardiorespiratory fitness, postural control, pain and disability after HIT versus MIT, 3) to which extent depressive mood and anxiety moderate the effects of HIT on diaphragm functioning in persons with chronic nonspecific low back pain (CNSLBP). The investigators hypothize that HIT improves diaphragm functioning more compared to MIT in persons with CNSLBP.
Status | Recruiting |
Enrollment | 64 |
Est. completion date | November 1, 2025 |
Est. primary completion date | June 1, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criterian (CNSLBP patients): - Dutch-speaking - Adults (age 18-65 years) - Chronic low back pain (i.e. pain localized below the costal margin and above the inferior gluteal folds, with or without referred leg pain for a period of at least twelve weeks), with a non-specific origin (i.e. pain of a nociceptive mechanical nature, not attributable to a recognizable, known, specific pathology, e.g. infection, tumour, osteoporosis, fracture, structural deformity, inflammatory disorder, radicular syndrome, or cauda equina syndrome) Exclusion Criteria (CNSLBP patients): - History of spinal fusion - A musculoskeletal disorder aside from chronic nonspecific low back pain that could affect the correct execution of the therapy program - Baseline characteristics that could affect the evaluation of the outcomes (a pacemaker, a chronic obstructive respiratory disorder, or known balance/vestibular problems) - Severe comorbidities (e.g., paresis or sensory disturbances of neurological origin, diabetes mellitus, rheumatoid arthritis) - Ongoing compensation claims - Negative advice from the general practitioner regarding sports medical screening - Pregnancy - Persons that are not able to attend regular appointments Inclusion Criteria (healthy volunteers): - Dutch-speaking - Adults (age 18-65 years) - No acute or chronic complaints Exclusion Criteria (healthy volunteers): - History of spinal fusion - Baseline characteristics that could affect the evaluation of the outcomes (a pacemaker, a chronic obstructive respiratory disorder, or known balance/vestibular problems) - Severe comorbidities (e.g., paresis or sensory disturbances of neurological origin, diabetes mellitus, rheumatoid arthritis) - Ongoing compensation claims - Negative advice from the general practitioner regarding sports medical screening - Pregnancy |
Country | Name | City | State |
---|---|---|---|
Belgium | Hasselt University | Diepenbeek | Limburg |
Lead Sponsor | Collaborator |
---|---|
Hasselt University | KU Leuven, Maastricht University |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Diaphragm strength | Maximal inspiratory pressure (MIP) is a reliable measure to quantify inspiratory muscle strength. MIP will be measured at residual volume according to the method of Black and Hyatt using an electronic pressure transducer (POWERbreathe International Ltd., type KH2, Warwickshire, UK). A minimum of five repetitions will be performed, and tests will be repeated until there is less than 5% difference between the best and second-best test. The highest pressure sustained over 1 s will be defined as MIP, and compared with reference values. | PRE (baseline) | |
Primary | Diaphragm strength | Maximal inspiratory pressure (MIP) is a reliable measure to quantify inspiratory muscle strength. MIP will be measured at residual volume according to the method of Black and Hyatt using an electronic pressure transducer (POWERbreathe International Ltd., type KH2, Warwickshire, UK). A minimum of five repetitions will be performed, and tests will be repeated until there is less than 5% difference between the best and second-best test. The highest pressure sustained over 1 s will be defined as MIP. | MID (6 weeks) | |
Primary | Diaphragm strength | Maximal inspiratory pressure (MIP) is a reliable measure to quantify inspiratory muscle strength. MIP will be measured at residual volume according to the method of Black and Hyatt using an electronic pressure transducer (POWERbreathe International Ltd., type KH2, Warwickshire, UK). A minimum of five repetitions will be performed, and tests will be repeated until there is less than 5% difference between the best and second-best test. The highest pressure sustained over 1 s will be defined as MIP. | POST (12 weeks) | |
Primary | Diaphragm strength | Maximal inspiratory pressure (MIP) is a reliable measure to quantify inspiratory muscle strength. MIP will be measured at residual volume according to the method of Black and Hyatt using an electronic pressure transducer (POWERbreathe International Ltd., type KH2, Warwickshire, UK). A minimum of five repetitions will be performed, and tests will be repeated until there is less than 5% difference between the best and second-best test. The highest pressure sustained over 1 s will be defined as MIP. | FU1 (3 months follow-up) | |
Primary | Diaphragm strength | Maximal inspiratory pressure (MIP) is a reliable measure to quantify inspiratory muscle strength. MIP will be measured at residual volume according to the method of Black and Hyatt using an electronic pressure transducer (POWERbreathe International Ltd., type KH2, Warwickshire, UK). A minimum of five repetitions will be performed, and tests will be repeated until there is less than 5% difference between the best and second-best test. The highest pressure sustained over 1 s will be defined as MIP. | FU2 (12 months follow-up) | |
Primary | Diaphragm endurance | Participants will undergo an inspiratory resistive loading protocol at a fixed intensity of 80% of MIP (POWERbreathe International Ltd., type KH2, Warwickshire, UK). The participants will be instructed to inhale maximally and as rapidly as possible at a frequency of 15 breaths/minute and a 0.5 duty cycle. The time to task failure will be recorded as the inspiratory muscle endurance time. | PRE (baseline) | |
Primary | Diaphragm endurance | Participants will undergo an inspiratory resistive loading protocol at a fixed intensity of 80% of MIP (POWERbreathe International Ltd., type KH2, Warwickshire, UK). The participants will be instructed to inhale maximally and as rapidly as possible at a frequency of 15 breaths/minute and a 0.5 duty cycle. The time to task failure will be recorded as the inspiratory muscle endurance time. | POST (12 weeks) | |
Primary | Diaphragm fatigue | Diaphragm fatigue is defined as a reduction in the ability to produce force/pressure following contractile activity. First, MIP will be measured using an electronic pressure transducer (POWERbreathe International Ltd., type KH2, Warwickshire, UK). Then, the participant will perform a maximal cardiopulmonary exercise test (CPET). After the CPET, the MIP-measurement will be repeated. The difference between the MIP before and after the CPET will be used as a measure of diaphragm fatigue. | PRE (baseline) | |
Primary | Diaphragm fatigue | Diaphragm fatigue is defined as a reduction in the ability to produce force/pressure following contractile activity. First, MIP will be measured using an electronic pressure transducer ((POWERbreathe International Ltd., type KH2, Warwickshire, UK). Then, the participant will perform a maximal cardiopulmonary exercise test (CPET). After the CPET, the MIP-measurement will be repeated. The difference between the MIP before and after the CPET will be used as a measure of diaphragm fatigue. | MID (6 weeks) | |
Primary | Diaphragm fatigue | Diaphragm fatigue is defined as a reduction in the ability to produce force/pressure following contractile activity. First, MIP will be measured using an electronic pressure transducer (POWERbreathe International Ltd., type KH2, Warwickshire, UK). Then, the participant will perform a maximal cardiopulmonary exercise test (CPET). After the CPET, the MIP-measurement will be repeated. The difference between the MIP before and after the CPET will be used as a measure of diaphragm fatigue. | POST (12 weeks) | |
Primary | Diaphragm fatigue | Diaphragm fatigue is defined as a reduction in the ability to produce force/pressure following contractile activity. First, MIP will be measured using an electronic pressure transducer (POWERbreathe International Ltd., type KH2, Warwickshire, UK). Then, the participant will perform a maximal cardiopulmonary exercise test (CPET). After the CPET, the MIP-measurement will be repeated. The difference between the MIP before and after the CPET will be used as a measure of diaphragm fatigue. | FU1 (3 months follow-up) | |
Primary | Diaphragm fatigue | Diaphragm fatigue is defined as a reduction in the ability to produce force/pressure following contractile activity. First, MIP will be measured using an electronic pressure transducer (POWERbreathe International Ltd., type KH2, Warwickshire, UK). Then, the participant will perform a maximal cardiopulmonary exercise test (CPET). After the CPET, the MIP-measurement will be repeated. The difference between the MIP before and after the CPET will be used as a measure of diaphragm fatigue. | FU2 (12 months follow-up) | |
Primary | Diaphragm activation (amplitude) | Diaphragm activation will be measured in terms of electromyography (EMG) amplitude. Surface EMG will be acquired throughout the postural control tasks and cardiopulmonary exercise test to measure muscle activation from the costal diaphragm/intercostals, scalene, parasternal intercostal, and sternocleidomastoid. | PRE (baseline) | |
Primary | Diaphragm activation (amplitude) | Diaphragm activation will be measured in terms of electromyography (EMG) amplitude. Surface EMG will be acquired throughout the postural control tasks and cardiopulmonary exercise test to measure muscle activation from the costal diaphragm/intercostals, scalene, parasternal intercostal, and sternocleidomastoid. | MID (6 weeks) | |
Primary | Diaphragm activation (amplitude) | Diaphragm activation will be measured in terms of electromyography (EMG) amplitude. Surface EMG will be acquired throughout the postural control tasks and cardiopulmonary exercise test to measure muscle activation from the costal diaphragm/intercostals, scalene, parasternal intercostal, and sternocleidomastoid. | POST (12 weeks) | |
Primary | Diaphragm activation (amplitude) | Diaphragm activation will be measured in terms of electromyography (EMG) amplitude. Surface EMG will be acquired throughout the postural control tasks and cardiopulmonary exercise test to measure muscle activation from the costal diaphragm/intercostals, scalene, parasternal intercostal, and sternocleidomastoid. | FU1 (3 months follow-up) | |
Primary | Diaphragm activation (amplitude) | Diaphragm activation will be measured in terms of electromyography (EMG) amplitude. Surface EMG will be acquired throughout the postural control tasks and cardiopulmonary exercise test to measure muscle activation from the costal diaphragm/intercostals, scalene, parasternal intercostal, and sternocleidomastoid. | FU2 (12 months follow-up) | |
Primary | Diaphragm activation (timing) | Diaphragm activation will be measured in terms of electromyography (EMG) timing. Surface EMG will be acquired throughout the postural control tasks and cardiopulmonary exercise test to measure muscle activation from the costal diaphragm/intercostals, scalene, parasternal intercostal, and sternocleidomastoid. | PRE (baseline) | |
Primary | Diaphragm activation (timing) | Diaphragm activation will be measured in terms of electromyography (EMG) timing. Surface EMG will be acquired throughout the postural control tasks and cardiopulmonary exercise test to measure muscle activation from the costal diaphragm/intercostals, scalene, parasternal intercostal, and sternocleidomastoid. | MID (6 weeks) | |
Primary | Diaphragm activation (timing) | Diaphragm activation will be measured in terms of electromyography (EMG) timing. Surface EMG will be acquired throughout the postural control tasks and cardiopulmonary exercise test to measure muscle activation from the costal diaphragm/intercostals, scalene, parasternal intercostal, and sternocleidomastoid. | POST (12 weeks) | |
Primary | Diaphragm activation (timing) | Diaphragm activation will be measured in terms of electromyography (EMG) timing. Surface EMG will be acquired throughout the postural control tasks and cardiopulmonary exercise test to measure muscle activation from the costal diaphragm/intercostals, scalene, parasternal intercostal, and sternocleidomastoid. | FU1 (3 months follow-up) | |
Primary | Diaphragm activation (timing) | Diaphragm activation will be measured in terms of electromyography (EMG) timing. Surface EMG will be acquired throughout the postural control tasks and cardiopulmonary exercise test to measure muscle activation from the costal diaphragm/intercostals, scalene, parasternal intercostal, and sternocleidomastoid. | FU2 (12 months follow-up) | |
Secondary | Modified Oswestry Disability Index (MODI) | The Modified Oswestry Disability Index is a valid and reliable questionnaire for evaluating constraints experienced by people in their daily activities due to chronic low back pain. It consists of ten items scored on a five-point scale. The total score is expressed in percentage (min. 0%, max. 100%) and displays the degree of functional limitation. A higher score indicates a higher degree of functional limitation. | PRE (baseline) | |
Secondary | Modified Oswestry Disability Index (MODI) | The Modified Oswestry Disability Index is a valid and reliable questionnaire for evaluating constraints experienced by people in their daily activities due to chronic low back pain. It consists of ten items scored on a five-point scale. The total score is expressed in percentage (min. 0%, max. 100%) and displays the degree of functional limitation. A higher score indicates a higher degree of functional limitation. | MID (6 weeks) | |
Secondary | Modified Oswestry Disability Index (MODI) | The Modified Oswestry Disability Index is a valid and reliable questionnaire for evaluating constraints experienced by people in their daily activities due to chronic low back pain. It consists of ten items scored on a five-point scale. The total score is expressed in percentage (min. 0%, max. 100%) and displays the degree of functional limitation. A higher score indicates a higher degree of functional limitation. | POST (12 weeks) | |
Secondary | Modified Oswestry Disability Index (MODI) | The Modified Oswestry Disability Index is a valid and reliable questionnaire for evaluating constraints experienced by people in their daily activities due to chronic low back pain. It consists of ten items scored on a five-point scale. The total score is expressed in percentage (min. 0%, max. 100%) and displays the degree of functional limitation. A higher score indicates a higher degree of functional limitation. | FU1 (3 months follow-up) | |
Secondary | Modified Oswestry Disability Index (MODI) | The Modified Oswestry Disability Index is a valid and reliable questionnaire for evaluating constraints experienced by people in their daily activities due to chronic low back pain. It consists of ten items scored on a five-point scale. The total score is expressed in percentage (min. 0%, max. 100%) and displays the degree of functional limitation. A higher score indicates a higher degree of functional limitation. | FU2 (12 months follow-up) | |
Secondary | Brief Pain Inventory (BPI) | The Brief Pain Inventory assesses the severity of pain, its impact on functioning, the location of pain, pain medications, and the amount of pain relief in the past 24 hours. The body chart of this questionnaire will be used to record the extent of pain, using the pain drawing method. The extent of pain might indicate the presence of widespread pain, which has been associated with altered nociceptive pain processing in chronic joint pain. The BPI scale defines pain as follows:
Worst Pain Score: 1 - 4 = Mild Pain Worst Pain Score: 5 - 6 = Moderate Pain Worst Pain Score: 7 - 10 = Severe Pain |
PRE (baseline) | |
Secondary | Brief Pain Inventory (BPI) | The Brief Pain Inventory assesses the severity of pain, its impact on functioning, the location of pain, pain medications, and the amount of pain relief in the past 24 hours. The body chart of this questionnaire will be used to record the extent of pain, using the pain drawing method. The extent of pain might indicate the presence of widespread pain, which has been associated with altered nociceptive pain processing in chronic joint pain. The BPI scale defines pain as follows:
Worst Pain Score: 1 - 4 = Mild Pain Worst Pain Score: 5 - 6 = Moderate Pain Worst Pain Score: 7 - 10 = Severe Pain |
MID (6 weeks) | |
Secondary | Brief Pain Inventory (BPI) | The Brief Pain Inventory assesses the severity of pain, its impact on functioning, the location of pain, pain medications, and the amount of pain relief in the past 24 hours. The body chart of this questionnaire will be used to record the extent of pain, using the pain drawing method. The extent of pain might indicate the presence of widespread pain, which has been associated with altered nociceptive pain processing in chronic joint pain. The BPI scale defines pain as follows:
Worst Pain Score: 1 - 4 = Mild Pain Worst Pain Score: 5 - 6 = Moderate Pain Worst Pain Score: 7 - 10 = Severe Pain |
POST (12 weeks) | |
Secondary | Brief Pain Inventory (BPI) | The Brief Pain Inventory assesses the severity of pain, its impact on functioning, the location of pain, pain medications, and the amount of pain relief in the past 24 hours. The body chart of this questionnaire will be used to record the extent of pain, using the pain drawing method. The extent of pain might indicate the presence of widespread pain, which has been associated with altered nociceptive pain processing in chronic joint pain. The BPI scale defines pain as follows:
Worst Pain Score: 1 - 4 = Mild Pain Worst Pain Score: 5 - 6 = Moderate Pain Worst Pain Score: 7 - 10 = Severe Pain |
FU1 (3 months follow-up) | |
Secondary | Brief Pain Inventory (BPI) | The Brief Pain Inventory assesses the severity of pain, its impact on functioning, the location of pain, pain medications, and the amount of pain relief in the past 24 hours. The body chart of this questionnaire will be used to record the extent of pain, using the pain drawing method. The extent of pain might indicate the presence of widespread pain, which has been associated with altered nociceptive pain processing in chronic joint pain. The BPI scale defines pain as follows:
Worst Pain Score: 1 - 4 = Mild Pain Worst Pain Score: 5 - 6 = Moderate Pain Worst Pain Score: 7 - 10 = Severe Pain |
FU2 (12 months follow-up) | |
Secondary | Beck Depression Inventory (BDI) | The Beck Depression Inventory is widely used as a self-reported questionnaire for assessing depression in patients with chronic pain. It consists of 21 items scored on a four-point scale (0-3). Item scores are summed to obtain the total score, with a higher total score indicating greater depression. | PRE (baseline) | |
Secondary | Beck Depression Inventory (BDI) | The Beck Depression Inventory is widely used as a self-reported questionnaire for assessing depression in patients with chronic pain. It consists of 21 items scored on a four-point scale (0-3). Item scores are summed to obtain the total score, with a higher total score indicating greater depression. | POST (12 weeks) | |
Secondary | Beck Depression Inventory (BDI) | The Beck Depression Inventory is widely used as a self-reported questionnaire for assessing depression in patients with chronic pain. It consists of 21 items scored on a four-point scale (0-3). Item scores are summed to obtain the total score, with a higher total score indicating greater depression. | FU2 (12 months follow-up) | |
Secondary | State-Trait Anxiety Inventory (STAI) | The State-Trait Anxiety Inventory is a questionnaire for assessing state anxiety (i.e. anxiety about an event) and trait anxiety (i.e. anxiety as a personal characteristic). It consists of 40 items scored on a four-point scale. Item scores are added to obtain the total score. The score of the STAI varies from a minimum score of 20 to a maximum score of 80 on both the STAI-state and STAI-trait subscales. STAI scores are commonly classified as "no or low anxiety" (20-37), "moderate anxiety" (38-44), and "high anxiety" (45-80). | PRE (baseline) | |
Secondary | State-Trait Anxiety Inventory (STAI) | The State-Trait Anxiety Inventory is a questionnaire for assessing state anxiety (i.e. anxiety about an event) and trait anxiety (i.e. anxiety as a personal characteristic). It consists of 40 items scored on a four-point scale. Item scores are added to obtain the total score. The score of the STAI varies from a minimum score of 20 to a maximum score of 80 on both the STAI-state and STAI-trait subscales. STAI scores are commonly classified as "no or low anxiety" (20-37), "moderate anxiety" (38-44), and "high anxiety" (45-80). | POST (12 weeks) | |
Secondary | State-Trait Anxiety Inventory (STAI) | The State-Trait Anxiety Inventory is a questionnaire for assessing state anxiety (i.e. anxiety about an event) and trait anxiety (i.e. anxiety as a personal characteristic). It consists of 40 items scored on a four-point scale. Item scores are added to obtain the total score. The score of the STAI varies from a minimum score of 20 to a maximum score of 80 on both the STAI-state and STAI-trait subscales. STAI scores are commonly classified as "no or low anxiety" (20-37), "moderate anxiety" (38-44), and "high anxiety" (45-80). | FU2 (12 months follow-up) | |
Secondary | Relative proprioceptive weighting ratio | A force plate will measure center of pressure (COP) displacement in response to ankle and lumbar muscle vibration during upright standing. If a person relies on proprioception from the vibrated muscle, an illusion of loss of balance will occur. To compensate, participants will move their COP in the opposite direction. When the triceps surae muscles are vibrated, a postural sway in a backward direction is expected, whereas during lumbar paraspinal muscle vibration, a forward postural body sway is expected. The amount of COP displacement during local vibration may represent the extent to which a person makes use of the proprioceptive signals of the vibrated muscles to maintain the upright posture. Reliance on ankle vs. lumbar proprioception will be calculated as the Relative Proprioceptive Weighting (RPW) ratio: RPW= AbsAnkle/(AbsAnkle + AbsLumbar). 'AbsAnkle' and 'AbsLumbar' refer to the absolute COP displacement during ankle and lumbar muscle vibration, respectively. | PRE (baseline) | |
Secondary | Relative proprioceptive weighting ratio | A force plate will measure center of pressure (COP) displacement in response to ankle and lumbar muscle vibration during upright standing. If a person relies on proprioception from the vibrated muscle, an illusion of loss of balance will occur. To compensate, participants will move their COP in the opposite direction. When the triceps surae muscles are vibrated, a postural sway in a backward direction is expected, whereas during lumbar paraspinal muscle vibration, a forward postural body sway is expected. The amount of COP displacement during local vibration may represent the extent to which a person makes use of the proprioceptive signals of the vibrated muscles to maintain the upright posture. Reliance on ankle vs. lumbar proprioception will be calculated as the Relative Proprioceptive Weighting (RPW) ratio: RPW= AbsAnkle/(AbsAnkle + AbsLumbar). 'AbsAnkle' and 'AbsLumbar' refer to the absolute COP displacement during ankle and lumbar muscle vibration, respectively. | MID (6 weeks) | |
Secondary | Relative proprioceptive weighting ratio | A force plate will measure center of pressure (COP) displacement in response to ankle and lumbar muscle vibration during upright standing. If a person relies on proprioception from the vibrated muscle, an illusion of loss of balance will occur. To compensate, participants will move their COP in the opposite direction. When the triceps surae muscles are vibrated, a postural sway in a backward direction is expected, whereas during lumbar paraspinal muscle vibration, a forward postural body sway is expected. The amount of COP displacement during local vibration may represent the extent to which a person makes use of the proprioceptive signals of the vibrated muscles to maintain the upright posture. Reliance on ankle vs. lumbar proprioception will be calculated as the Relative Proprioceptive Weighting (RPW) ratio: RPW= AbsAnkle/(AbsAnkle + AbsLumbar). 'AbsAnkle' and 'AbsLumbar' refer to the absolute COP displacement during ankle and lumbar muscle vibration, respectively. | POST (12 weeks) | |
Secondary | Relative proprioceptive weighting ratio | A force plate will measure center of pressure (COP) displacement in response to ankle and lumbar muscle vibration during upright standing. If a person relies on proprioception from the vibrated muscle, an illusion of loss of balance will occur. To compensate, participants will move their COP in the opposite direction. When the triceps surae muscles are vibrated, a postural sway in a backward direction is expected, whereas during lumbar paraspinal muscle vibration, a forward postural body sway is expected. The amount of COP displacement during local vibration may represent the extent to which a person makes use of the proprioceptive signals of the vibrated muscles to maintain the upright posture. Reliance on ankle vs. lumbar proprioception will be calculated as the Relative Proprioceptive Weighting (RPW) ratio: RPW= AbsAnkle/(AbsAnkle + AbsLumbar). 'AbsAnkle' and 'AbsLumbar' refer to the absolute COP displacement during ankle and lumbar muscle vibration, respectively. | FU1 (3 months follow-up) | |
Secondary | Relative proprioceptive weighting ratio | A force plate will measure center of pressure (COP) displacement in response to ankle and lumbar muscle vibration during upright standing. If a person relies on proprioception from the vibrated muscle, an illusion of loss of balance will occur. To compensate, participants will move their COP in the opposite direction. When the triceps surae muscles are vibrated, a postural sway in a backward direction is expected, whereas during lumbar paraspinal muscle vibration, a forward postural body sway is expected. The amount of COP displacement during local vibration may represent the extent to which a person makes use of the proprioceptive signals of the vibrated muscles to maintain the upright posture. Reliance on ankle vs. lumbar proprioception will be calculated as the Relative Proprioceptive Weighting (RPW) ratio: RPW= AbsAnkle/(AbsAnkle + AbsLumbar). 'AbsAnkle' and 'AbsLumbar' refer to the absolute COP displacement during ankle and lumbar muscle vibration, respectively. | FU2 (12 months follow-up) | |
Secondary | Thermal Detection and Pain Threshold Temperatures | Thermal Quantitative sensory testing (QST) will be used to investigate nociceptive stimulus processing. QST is a non-invasive examination of the somatosensory system commonly used in pain diagnosis. The Medoc Advanced Thermosensory Stimulator (TSA) - 2 system will be used to perform a standardized test protocol.
Detection and pain threshold temperatures (in °C) will be assessed locally (at the most painful site of the lower back) and remotely (at the contralateral wrist) using the TSA limits protocol: Cold Detection Threshold (CDT) Warmth Detection Threshold (WDT) Cold Pain Threshold (CPT) Heat Pain Threshold (HPT) |
PRE (baseline) | |
Secondary | Thermal Detection and Pain Threshold Temperatures | Thermal Quantitative sensory testing (QST) will be used to investigate nociceptive stimulus processing. QST is a non-invasive examination of the somatosensory system commonly used in pain diagnosis. The Medoc Advanced Thermosensory Stimulator (TSA) - 2 system will be used to perform a standardized test protocol.
Detection and pain threshold temperatures (in °C) will be assessed locally (at the most painful site of the lower back) and remotely (at the contralateral wrist) using the TSA limits protocol: Cold Detection Threshold (CDT) Warmth Detection Threshold (WDT) Cold Pain Threshold (CPT) Heat Pain Threshold (HPT) |
MID (6 weeks) | |
Secondary | Thermal Detection and Pain Threshold Temperatures | Thermal Quantitative sensory testing (QST) will be used to investigate nociceptive stimulus processing. QST is a non-invasive examination of the somatosensory system commonly used in pain diagnosis. The Medoc Advanced Thermosensory Stimulator (TSA) - 2 system will be used to perform a standardized test protocol.
Detection and pain threshold temperatures (in °C) will be assessed locally (at the most painful site of the lower back) and remotely (at the contralateral wrist) using the TSA limits protocol: Cold Detection Threshold (CDT) Warmth Detection Threshold (WDT) Cold Pain Threshold (CPT) Heat Pain Threshold (HPT) |
POST (12 weeks) | |
Secondary | Thermal Detection and Pain Threshold Temperatures | Thermal Quantitative sensory testing (QST) will be used to investigate nociceptive stimulus processing. QST is a non-invasive examination of the somatosensory system commonly used in pain diagnosis. The Medoc Advanced Thermosensory Stimulator (TSA) - 2 system will be used to perform a standardized test protocol.
Detection and pain threshold temperatures (in °C) will be assessed locally (at the most painful site of the lower back) and remotely (at the contralateral wrist) using the TSA limits protocol: Cold Detection Threshold (CDT) Warmth Detection Threshold (WDT) Cold Pain Threshold (CPT) Heat Pain Threshold (HPT) |
FU1 (3 months follow-up) | |
Secondary | Thermal Detection and Pain Threshold Temperatures | Thermal Quantitative sensory testing (QST) will be used to investigate nociceptive stimulus processing. QST is a non-invasive examination of the somatosensory system commonly used in pain diagnosis. The Medoc Advanced Thermosensory Stimulator (TSA) - 2 system will be used to perform a standardized test protocol.
Detection and pain threshold temperatures (in °C) will be assessed locally (at the most painful site of the lower back) and remotely (at the contralateral wrist) using the TSA limits protocol: Cold Detection Threshold (CDT) Warmth Detection Threshold (WDT) Cold Pain Threshold (CPT) Heat Pain Threshold (HPT) |
FU2 (12 months follow-up) | |
Secondary | Temporal Summation of Pain (TSP) | Thermal Quantitative sensory testing (QST) will be used to investigate nociceptive stimulus processing. QST is a non-invasive examination of the somatosensory system commonly used in pain diagnosis. The Medoc TSA-2 system will be used to perform a standardized test protocol.
Temporal summation of pain (TSP) will be assessed at the contralateral wrist using a 2-minute tonic heat stimulus and patient-controlled temperature. Participants are presented with a tonic heat stimulus and are instructed to maintain their initial sensation for two minutes via the remote controller. To quantify temporal adaptation and temporal summation of pain, the slope and magnitude of temperature changes will be extracted and the areas under the curve will be calculated. |
PRE (baseline) | |
Secondary | Temporal Summation of Pain (TSP) | Thermal Quantitative sensory testing (QST) will be used to investigate nociceptive stimulus processing. QST is a non-invasive examination of the somatosensory system commonly used in pain diagnosis. The Medoc TSA-2 system will be used to perform a standardized test protocol.
Temporal summation of pain (TSP) will be assessed at the contralateral wrist using a 2-minute tonic heat stimulus and patient-controlled temperature. Participants are presented with a tonic heat stimulus and are instructed to maintain their initial sensation for two minutes via the remote controller. To quantify temporal adaptation and temporal summation of pain, the slope and magnitude of temperature changes will be extracted and the areas under the curve will be calculated. |
MID (6 weeks) | |
Secondary | Temporal Summation of Pain (TSP) | Thermal Quantitative sensory testing (QST) will be used to investigate nociceptive stimulus processing. QST is a non-invasive examination of the somatosensory system commonly used in pain diagnosis. The Medoc TSA-2 system will be used to perform a standardized test protocol.
Temporal summation of pain (TSP) will be assessed at the contralateral wrist using a 2-minute tonic heat stimulus and patient-controlled temperature. Participants are presented with a tonic heat stimulus and are instructed to maintain their initial sensation for two minutes via the remote controller. To quantify temporal adaptation and temporal summation of pain, the slope and magnitude of temperature changes will be extracted and the areas under the curve will be calculated. |
POST (12 weeks) | |
Secondary | Temporal Summation of Pain (TSP) | Thermal Quantitative sensory testing (QST) will be used to investigate nociceptive stimulus processing. QST is a non-invasive examination of the somatosensory system commonly used in pain diagnosis. The Medoc TSA-2 system will be used to perform a standardized test protocol.
Temporal summation of pain (TSP) will be assessed at the contralateral wrist using a 2-minute tonic heat stimulus and patient-controlled temperature. Participants are presented with a tonic heat stimulus and are instructed to maintain their initial sensation for two minutes via the remote controller. To quantify temporal adaptation and temporal summation of pain, the slope and magnitude of temperature changes will be extracted and the areas under the curve will be calculated. |
FU1 (3 months follow-up) | |
Secondary | Temporal Summation of Pain (TSP) | Thermal Quantitative sensory testing (QST) will be used to investigate nociceptive stimulus processing. QST is a non-invasive examination of the somatosensory system commonly used in pain diagnosis. The Medoc TSA-2 system will be used to perform a standardized test protocol.
Temporal summation of pain (TSP) will be assessed at the contralateral wrist using a 2-minute tonic heat stimulus and patient-controlled temperature. Participants are presented with a tonic heat stimulus and are instructed to maintain their initial sensation for two minutes via the remote controller. To quantify temporal adaptation and temporal summation of pain, the slope and magnitude of temperature changes will be extracted and the areas under the curve will be calculated. |
FU2 (12 months follow-up) | |
Secondary | Conditioned Pain Modulation (CPM) | Thermal Quantitative sensory testing (QST) will be used to investigate nociceptive stimulus processing. The Medoc TSA-2 system will be used to perform a standardized test protocol.
Conditioned pain modulation will be evaluated using a Dual-Thermode program with two different stimuli: Test stimulus: this heat stimulus will be administered twice at the contralateral wrist. Once on its own before administering the conditioning stimulus, and once during the conditioning heat stimulus at the ipsilateral wrist. Conditioning stimulus: this heat stimulus will be administered at the ipsilateral wrist after first applying the test stimulus. The difference in pain intensity at the contralateral wrist during the stand-alone test stimulus and the test stimulus during the conditioning stimulus will be calculated. Pain intensity is assessed using a Numerical Pain Rating Scale (NPRS) ranging from 0 to 100, where 0 stands for "no pain", and 100 for "worst imaginable pain". |
PRE (baseline) | |
Secondary | Conditioned Pain Modulation (CPM) | Thermal Quantitative sensory testing (QST) will be used to investigate nociceptive stimulus processing. The Medoc TSA-2 system will be used to perform a standardized test protocol.
Conditioned pain modulation will be evaluated using a Dual-Thermode program with two different stimuli: Test stimulus: this heat stimulus will be administered twice at the contralateral wrist. Once on its own before administering the conditioning stimulus, and once during the conditioning heat stimulus at the ipsilateral wrist. Conditioning stimulus: this heat stimulus will be administered at the ipsilateral wrist after first applying the test stimulus. The difference in pain intensity at the contralateral wrist during the stand-alone test stimulus and the test stimulus during the conditioning stimulus will be calculated. Pain intensity is assessed using a Numerical Pain Rating Scale (NPRS) ranging from 0 to 100, where 0 stands for "no pain", and 100 for "worst imaginable pain". |
MID (6 weeks) | |
Secondary | Conditioned Pain Modulation (CPM) | Thermal Quantitative sensory testing (QST) will be used to investigate nociceptive stimulus processing. The Medoc TSA-2 system will be used to perform a standardized test protocol.
Conditioned pain modulation will be evaluated using a Dual-Thermode program with two different stimuli: Test stimulus: this heat stimulus will be administered twice at the contralateral wrist. Once on its own before administering the conditioning stimulus, and once during the conditioning heat stimulus at the ipsilateral wrist. Conditioning stimulus: this heat stimulus will be administered at the ipsilateral wrist after first applying the test stimulus. The difference in pain intensity at the contralateral wrist during the stand-alone test stimulus and the test stimulus during the conditioning stimulus will be calculated. Pain intensity is assessed using a Numerical Pain Rating Scale (NPRS) ranging from 0 to 100, where 0 stands for "no pain", and 100 for "worst imaginable pain". |
POST (12 weeks) | |
Secondary | Conditioned Pain Modulation (CPM) | Thermal Quantitative sensory testing (QST) will be used to investigate nociceptive stimulus processing. The Medoc TSA-2 system will be used to perform a standardized test protocol.
Conditioned pain modulation will be evaluated using a Dual-Thermode program with two different stimuli: Test stimulus: this heat stimulus will be administered twice at the contralateral wrist. Once on its own before administering the conditioning stimulus, and once during the conditioning heat stimulus at the ipsilateral wrist. Conditioning stimulus: this heat stimulus will be administered at the ipsilateral wrist after first applying the test stimulus. The difference in pain intensity at the contralateral wrist during the stand-alone test stimulus and the test stimulus during the conditioning stimulus will be calculated. Pain intensity is assessed using a Numerical Pain Rating Scale (NPRS) ranging from 0 to 100, where 0 stands for "no pain", and 100 for "worst imaginable pain". |
FU1 (3 months follow-up) | |
Secondary | Conditioned Pain Modulation (CPM) | Thermal Quantitative sensory testing (QST) will be used to investigate nociceptive stimulus processing. The Medoc TSA-2 system will be used to perform a standardized test protocol.
Conditioned pain modulation will be evaluated using a Dual-Thermode program with two different stimuli: Test stimulus: this heat stimulus will be administered twice at the contralateral wrist. Once on its own before administering the conditioning stimulus, and once during the conditioning heat stimulus at the ipsilateral wrist. Conditioning stimulus: this heat stimulus will be administered at the ipsilateral wrist after first applying the test stimulus. The difference in pain intensity at the contralateral wrist during the stand-alone test stimulus and the test stimulus during the conditioning stimulus will be calculated. Pain intensity is assessed using a Numerical Pain Rating Scale (NPRS) ranging from 0 to 100, where 0 stands for "no pain", and 100 for "worst imaginable pain". |
FU2 (12 months follow-up) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01659073 -
Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation
|
N/A | |
Recruiting |
NCT05914311 -
Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration
|
N/A | |
Recruiting |
NCT05422456 -
The Turkish Version of Functional Disability Inventory
|
||
Enrolling by invitation |
NCT05422443 -
The Turkish Version of Pain Coping Questionnaire
|
||
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04385030 -
Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury
|
N/A | |
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05103319 -
Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
|
||
Completed |
NCT03687762 -
Back on Track to Healthy Living Study
|
N/A | |
Completed |
NCT04171336 -
Animal-assisted Therapy for Children and Adolescents With Chronic Pain
|
N/A | |
Completed |
NCT03179475 -
Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
|
Phase 4 | |
Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Recruiting |
NCT06060028 -
The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain
|
N/A | |
Recruiting |
NCT06204627 -
TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain
|
N/A | |
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00983385 -
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
|
Phase 3 | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Terminated |
NCT03538444 -
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
|
N/A | |
Not yet recruiting |
NCT05812703 -
Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain
|